The aim of our work at IGENOMIX is to help families to achieve a pregnancy that will lead to a healthy baby at home.
There are two principal factors to consider to maximize the chances of implantation during an IVF treatment: a chromosomally normal embryo and a receptive endometrium.
According to internal data and several independent clinical studies, selecting normal embryos might increase the pregnancy possibilities after transfer.
The PGS increases the possibility of having a healthy baby, as it allows chromosomally normal embryos to be identified.
The mean theoretical time to achieve a LB (weeks) decreases from 14.9 to 7.7 weeks with PGS (1)
PGS helps to avoid repeating cycles of assisted reproduction and can help to reduce the number of multiple pregnancies performing by supporting single embryo transfer
If both the embryo and the endometrium are synchronized, the IVF clinician can transfer the right embryo at the right time.
Combining IGENOMIX ERA and PGT-A allows to cover the two key factors to achieve your goal, a healthy baby at home.
An endometrium is receptive when it is ready for embryo implantation. This occurs around days 19-21 in each menstrual cycle of a fertile woman. This period of receptivity is what we call the window of implantation.
The lack of synchronisation between the embryo ready to be implanted and endometrial receptivity is one of the causes of recurring implantation failure. This is why it is recommended to assess the endometrium in order to determine the optimal day for embryo transfer.
The ERA test requires an endometrial biopsy that should be carried out on day LH+7 (natural cycle) or day P+5 (HRT cycle). This biopsy is quickly and easily taken by a gynecologist in their consultation room and sent to Igenomix for testing.
The ERA test analyzes the expression levels of 236 genes linked to the status of endometrial receptivity, using RNA sequencing taken from the endometrial tissue.
Following the analysis, a specific computational predictor classifies the samples according to their expression profile as Receptive or Non-Receptive.
The Endometrial Receptivity Analysis (ERA®) has been designed, developed and patented by IGENOMIX (PCT/ES2009/000386).
ERA tests performed
1: Rubio et al: In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil Steril. 2017 May;107(5):1122-1129.
2: Rubio et al: Preimplantation genetic screening using fluorescence in situ hybridization inpatients with repetitive implantation failure and advanced maternal age: two randomized trials. Fertil Steril. 2013 Apr;99(5):1400-7
3: What a difference two days make: “personalized” embryo transfer (pET) paradigm: a case report and pilot study. Hum Reprod. 2014 Jun;29(6):1244-7. doi: 10.1093/humrep/deu070. Epub 2014 Apr 15. PubMed PMID: 24737781. Ruiz-Alonso M, Galindo N, Pellicer A, Simón C.
4: A Genomic Diagnostic Tool for Human Endometrial Receptivity based on the Transcriptomic Signature. Fertil Steril.2011. 95(1)pp: 50-60, 60.e1-15 Díaz-Ginemo P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C
5: The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure.. Fertil Steril. 2013 Sep;100(3):818-24. doi: 10.1016/j.fertnstert.2013.05.004. Epub 2013 Jun 4.PubMed [journal]PMID:23756099 Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F, Carrera J, Vilella F, Pellicer A, Simón C.
6: The accuracy and reproducibility of the endometrial receptivity array is superior to histology as a diagnostic method for endometrial receptivity.. Fertil Steril. 2013 Feb;99(2):508-17. doi: 10.1016/j.fertnstert.2012.09.046. Epub 2012 Oct 23 Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P, Garrido N, Pellicer A, Simón C.